Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, open, single-arm, the real world of clinical trials. The researchers plan to recruit 300 eligible patients. The main purpose of this study is to evaluate the effectiveness and safety of butylphthalide in the treatment of ischemic stroke, and to establish a population pharmacokinetic model of butylphthalide in elderly patients to explore its blood drug concentration. Correlation with its efficacy and adverse reactions.
Ischemic stroke is one of the diseases that seriously threaten human health, with the characteristics of high incidence, high disability and high recurrence rate. Patients will not only suffer from impaired physical function, but also mental symptoms, social function and other obstacles, which seriously affect the quality of life.
Butylphthalide can improve the damage of central nervous system in patients with acute ischemic stroke, and can promote the improvement of patients with neurological deficits. Regarding the treatment of ischemic stroke with butylphthalide, there is still a lack of big data research based on real-world efficacy and safety; there is a lack of data on the pharmacokinetics of elderly patients and their correlation with adverse reactions.
Thus, it is estimated that 300 patients will be enrolled and given intravenous butylphthalide sodium chloride injection 25mg twice a day for 7-14 days, and then oral butylphthalide soft capsule 0.2g three times a day for 76-83 days. The patients will be collected for experiment before and after treatment. Laboratory data, electrocardiogram, NIHSS, mRS, combined medication and adverse events, etc., to evaluate the effectiveness and safety of butylphthalide in the treatment of ischemic stroke. In addition, a population pharmacokinetic model of butylphthalide in elderly patients was established for 50 of them.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A group of patients with ischemic stroke were treated with butylphthalide injection and capsules | Experimental | Patients eligible for inclusion and exclusion are only divided into one group, no controls or other. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Butylphthalide | Drug | Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days. |
| Measure | Description | Time Frame |
|---|---|---|
| The incidence of adverse events caused by treatment | In a clinical trial, the probability of an unexpected and adverse medical event that occurs after a patient or clinical subject receives a trial drug, but it does not necessarily have a causal relationship with the treatment. | 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| NIHSS | NIH stroke scale (NIHSS) to assess the degree of neurological deficit in stroke patients. The score ranges from 0 to 42 points, the higher the score, the more severe the nerve damage. Patients with a baseline assessment of> 16 points are likely to die, while those with a score of <6 are likely to recover well; for each additional point, the probability of a good prognosis is reduced by 17% |
| Measure | Description | Time Frame |
|---|---|---|
| hemoglobin concentration | The normal range of hemoglobin concentration is 120-160g/L for adult males and 110-150g/L for adult females | 90days |
| ECG | The electrocardiogram (ECG) mainly checks whether the patient's heart rate, PR interval, QRS interval, and QT interval are within the normal range. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xueyan Cui | Contact | 15053180972 | qfscxy@126.com | |
| Shuxian Lv | Contact | 15154126233 |
| Name | Affiliation | Role |
|---|---|---|
| Xin Huang | Qianfoshan Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shandong Provincial Qianfoshan Hospital | Recruiting | Jinan | Shandong Provincial | China |
Not provided
Not provided
Not provided
Not provided
Not provided
A single-group clinical trial is a study with only one group, and no corresponding control group is designed for the experimental group.
Not provided
Not provided
Intervention measures are closer to the real-world clinical environment to make up for the shortcomings of RCT.
Not provided
|
| 90 days |
| mRS | Modified Rankin scale (mRS) is an indicator of the efficacy of functional disability. The score ranges from 0 to 5 points, and the clinical score will be increased to 6 points to indicate death. The higher the score, the more disability the patient is. | 90 days |
| Correlation between blood drug concentration and adverse events | Try to find the relationship between pharmacokinetic parameters and adverse events | 90 days |
| 90days |
| White blood cell count | White blood cell normal value parameters: adult white blood cell normal value (4.0~10.0)*109 /L | 90days |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002544 | Cerebral Infarction |
| D020520 | Brain Infarction |
| D002545 | Brain Ischemia |
| D009422 | Nervous System Diseases |
| D002493 | Central Nervous System Diseases |
| D014652 | Vascular Diseases |
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002318 | Cardiovascular Diseases |
| D007238 | Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009336 | Necrosis |
Not provided
Not provided
| ID | Term |
|---|---|
| C027125 | 3-n-butylphthalide |
Not provided
Not provided
Not provided